Posted inNeurology news Rheumatology
Pregnancy DMT Management in Multiple Sclerosis Increases Relapse Risk — Anti‑CD20 Before Conception Is Most Protective
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest risks, while preconception anti‑CD20 strategies are most protective.



















